Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies.
Cancer Cell. 2022 Jun 13;40(6):590-591. doi: 10.1016/j.ccell.2022.05.007. Epub 2022 May 16.
Cancer Cell. 2022.
PMID: 35598602
Free PMC article.
No abstract available.